Quarterly Financial Results and Stock Price Movements - Research Report on Quest Diagnostics, Zimmer, ResMed, Thoratec and

  Quarterly Financial Results and Stock Price Movements - Research Report on
          Quest Diagnostics, Zimmer, ResMed, Thoratec and CareFusion

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, November 6, 2013

NEW YORK, November 6, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Quest
Diagnostics Inc. (NYSE: DGX), Zimmer Holdings, Inc. (NYSE: ZMH), ResMed Inc.
(NYSE: RMD), Thoratec Corporation (NASDAQ: THOR) and CareFusion Corporation
(NYSE: CFN). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Quest Diagnostics Inc. Research Report

On November 1, 2013, Quest Diagnostics Inc.'s (Quest Diagnostics) stock
increased 1.70%, ending the day at $60.93 per share. Over the past three
trading days, Quest Diagnostics' stock rose 2.68%, compared to the Dow Jones
Industrial Average which went down 0.41% during the same period. The Full
Research Report on Quest Diagnostics Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

[http://www.analystscorner.com/r/full_research_report/05ba_DGX]

--

Zimmer Holdings, Inc. Research Report

On November 1, 2013, Zimmer Holdings, Inc.'s (Zimmer) stock closed at $87.89
per share, up 0.48%. Zimmer's stocks dropped 0.58% over the previous three
trading days, while the Dow Jones Industrial Average dropped 0.41% during the
same period. The Full Research Report on Zimmer Holdings, Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

[http://www.analystscorner.com/r/full_research_report/9db9_ZMH]

--

ResMed Inc. Research Report

On October 24, 2013, ResMed Inc. (ResMed) released its Q3 2013 results with
revenues of $357.7 million, marking an increase of 5.3% YoY. Net income for Q3
2013 came in at $80.9 million, up 13.6% YoY, while diluted EPS for the quarter
stood at $0.56, compared to $0.49 in Q3 2012. Mick Farrell, ResMed's CEO
commented, "In the first quarter of fiscal 2014, revenue in the Americas
increased by 4% over the prior year's quarter, to $201.5 million. Revenue
outside the Americas was $156.2 million, a 5% increase on a constant currency
basis, over the prior year's quarter. Global revenue growth was driven
primarily by sales of higher valued flow generators, like our S9 AutoSet™ and
S9™ bilevels, while mask spares and accessories did particularly well this
quarter. Operating profit for the September quarter was $96.9 million, cash
flow from operations was $90.4 million, while gross margin increased to 63.7%,
all demonstrating excellent operating performance." In addition, ResMed's
Board of Directors also declared a dividend of $0.25 per share, which is
payable on December 18, 2013 to shareholders of record on November 19, 2013.
The Full Research Report on ResMed Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

[http://www.analystscorner.com/r/full_research_report/bd44_RMD]

--

Thoratec Corporation Research Report

On October 30, 2013, Thoratec Corporation (Thoratec) released its Q3 2013
results with revenues of $126.4 million, up 7.4% YoY. During the quarter, the
Company also posted GAAP net income per diluted share of $0.32, compared with
GAAP net income per diluted share of $0.41 in Q3 2012. "Thoratec generated
strong results during the third quarter, highlighted by continued growth in
our HeartMate II® and CentriMag® product lines," said Gary F. Burbach,
President and CEO of Thoratec. "We continue to drive expansion of the
worldwide market for MCS therapy and delivered international revenue growth of
32% during the quarter." Thoratec increased its guidance for full-year 2013
net income per diluted share to $1.30-$1.35 on a GAAP basis and $1.80-1.85 on
a non-GAAP basis, and narrowed full-year 2013 revenue guidance to a range of
$500 million to $505 million. The Full Research Report on Thoratec Corporation
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/1bee_THOR]

--

CareFusion Corporation Research Report

On November 1, 2013, CareFusion Corporation's (CareFusion) stocks rose 0.34%
to end the day at $38.90 per share. Over the previous three day trading
period, CareFusion's stocks were down 1.17% compared to S&P 500 which dipped
0.58% during the same period. The Full Research Report on CareFusion
Corporation - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/4933_CFN]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.